Medicare Enrolled
Dr. Shachar Peles, M.D.
Hematology · Palm Springs, FL
Practice pattern: Mixed Practice
— Diverse clinical practice across multiple procedure types
Speaking/Promotional
Very High
DATA COVERAGE
Data in 4 of 4 federal sources
Measures public federal data availability — not provider quality
Informational, not a quality rating.
This page presents federal public records about Dr. Peles from CMS (NPPES, Open Payments, Medicare Provider Utilization, PECOS). It is not medical advice, an endorsement, or a judgment of clinical quality. Always consult the provider directly and a licensed clinician for medical decisions. Read methodology →
Are you Dr. Peles?
Request a correction or review of any data shown here. Provider portal →
What this data tells you about Dr. Peles
Dr. Shachar Peles is a hematology specialist in Palm Springs, FL, with 19 years of NPI registration. Based on federal Medicare data, Dr. Peles performed 175,748 Medicare services across 4,127 unique beneficiaries.
Between the years covered by Open Payments, Dr. Peles received a total of $212,694 from 95 pharmaceutical and/or device companies across 1234 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common in hematology. The majority of payments are for speaking programs and promotional activities, reflecting participation in industry-sponsored events. Patients may wish to discuss these relationships with their provider.
The Data Coverage level for Dr. Peles is Very High — reflecting how much public federal data is available about this provider. This is not a quality rating. Patients are encouraged to use this data as one of several factors when choosing a healthcare provider.
✓ 19 years in practice
▲ Top 28% volume in FL
$212,694 industry payments
Medicare Practice Summary
Medicare Utilization ↗175,748
Medicare services
Top 28% in FL for hematology
4,127
Unique beneficiaries
$17
Avg. Medicare payment
Medicare patients only (65+ / disabled) · Not a quality rating · How to read this →
~9,250 Medicare services per year of practice
Top procedures by volume
Ranked by number of services performed for Medicare patients. Avg. submitted charge is what the provider billed; avg. Medicare payment is what CMS paid.
| Procedure | Volume | Avg. paid | Avg. submitted |
|---|---|---|---|
| Daratumumab injection (Darzalex) | 27,360 | $38 | $110 |
| Filgrastim injection (Zarxio) for white blood cells | 25,200 | $0 | $2 |
| Iron infusion (Feraheme) | 23,460 | $0 | $4 |
| Pembrolizumab injection (Keytruda) | 19,000 | $43 | $137 |
| Anti-nausea injection (aprepitant) | 17,940 | $1 | $5 |
| Iron sucrose injection (Venofer) | 9,500 | $0 | $5 |
| Denosumab injection (Prolia/Xgeva) | 9,180 | $19 | $51 |
| Epoetin alfa injection (Procrit) for anemia | 8,581 | $6 | $23 |
| Immune globulin infusion (Gammagard) | 6,806 | $36 | $108 |
| Iron infusion (Monoferric) | 6,100 | $17 | $57 |
| Complete blood count (CBC) with differential | 3,091 | $8 | $29 |
| Dexamethasone injection (steroid) | 3,071 | $0 | $3 |
| Blood draw (venipuncture) | 2,803 | $8 | $9 |
| Contrast dye for imaging (iodine-based) | 2,260 | $0 | $1 |
| Anti-nausea injection (Aloxi/palonosetron) | 1,710 | $1 | $28 |
| Office visit, established patient (30-39 min) | 1,369 | $98 | $339 |
| Office visit, established patient (20-29 min) | 1,204 | $68 | $239 |
| Drug injection, under skin or into muscle | 970 | $11 | $69 |
| Injection, fluorouracil, 500 mg | 768 | $2 | $7 |
| Anti-nausea injection (ondansetron/Zofran) | 584 | $0 | $9 |
| Injection, vitamin b-12 cyanocobalamin, up to 1000 mcg | 514 | $1 | $6 |
| Administration of chemotherapy into vein, 1 hour or less | 491 | $104 | $378 |
| Injection of additional new drug or substance into vein | 452 | $12 | $61 |
| Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less | 391 | $50 | $189 |
| Injection, zoledronic acid, 1 mg | 385 | $7 | $69 |
| Infusion into a vein for therapy, prevention, or diagnosis, additional sequential infusion, 1 hour or less | 322 | $23 | $84 |
| Administration of non-hormonal anti-neoplastic chemotherapy under skin or into muscle | 247 | $57 | $206 |
| Injection, diphenhydramine hcl, up to 50 mg | 186 | $1 | $3 |
| Administration of chemotherapy into vein, each additional hour | 179 | $22 | $79 |
| Infusion into a vein for therapy, prevention, or diagnosis, each additional hour | 154 | $16 | $56 |
| Infusion into a vein for hydration, each additional hour | 107 | $10 | $42 |
| Administration of additional new drug or substance into vein using push technique | 94 | $45 | $170 |
| Infusion, normal saline solution , 1000 cc | 92 | $2 | $7 |
| Infusion into a vein for hydration, 31-60 minutes | 90 | $25 | $156 |
| New patient office visit (45-59 min) | 90 | $123 | $453 |
| Leuprolide acetate (for depot suspension), 7.5 mg | 90 | $139 | $562 |
| Administration of additional new drug or substance into vein, 1 hour or less | 72 | $52 | $178 |
| Chemotherapy administration, intravenous infusion technique; initiation of infusion in the office/clinic setting using office/clinic pump/supplies, with continuation of the infusion in the community setting (e.g., home, domiciliary, rest home or assisted l | 71 | $137 | $637 |
| Infusion into a vein for therapy, prevention, or diagnosis concurrent with another infusion | 69 | $16 | $56 |
| Office visit, established patient, complex (40-54 min) | 69 | $139 | $474 |
| Infusion, normal saline solution, sterile (500 ml = 1 unit) | 66 | $1 | $7 |
| Automated urinalysis | 62 | $2 | $8 |
| Red blood count automated, with additional calculations | 61 | $5 | $20 |
| Injection, methylprednisolone sodium succinate, up to 40 mg | 53 | $3 | $11 |
| Hospital follow-up visit, moderate complexity | 49 | $65 | $197 |
| Administration of hormonal anti-neoplastic chemotherapy under skin or into muscle | 41 | $26 | $89 |
| Injection of drug or substance into vein | 33 | $29 | $156 |
| Office or other outpatient visit for the evaluation and management of established patient that may not require presence of healthcare professional | 31 | $19 | $59 |
| Initial hospital admission, high complexity | 25 | $131 | $556 |
| Biopsy and aspiration of bone marrow sample for diagnosis | 24 | $126 | $467 |
| New patient office visit, complex (60-74 min) | 24 | $169 | $585 |
| Fluorodeoxyglucose f-18 fdg, diagnostic, per study dose, up to 45 millicuries | 24 | $401 | $680 |
| Nuclear medicine study from skull base to mid-thigh with ct scan | 23 | $1,164 | $3,706 |
| Ct scan of chest with contrast | 21 | $49 | $344 |
| CT scan of abdomen and pelvis with contrast | 20 | $185 | $550 |
| Hospital follow-up visit, high complexity | 18 | $97 | $285 |
| Drawing of blood for a medical problem | 14 | $73 | $277 |
| Initial hospital admission, moderate complexity | 14 | $107 | $377 |
| Echocardiogram, transthoracic | 12 | $103 | $430 |
| Advance care planning consultation, first 30 min | 11 | $67 | $225 |
How to read this data: This reflects Medicare patients only (typically 65+). Payment amounts are what Medicare paid the provider, not your out-of-pocket cost. A higher procedure volume generally indicates more experience with that procedure.
21.5% high complexity
73.3% medium
5.2% routine
Industry Payment Transparency
Open Payments through 2024 ↗$212,694
Total received (2018-2024)
Avg $30,385/year across 7 years
Top 1% in FL for hematology
95
Companies
1,234
Individual payments
All payments are legal and publicly reported · Not evidence of wrongdoing · How to interpret →
Payment profile
Industry payments classified by relationship type. Not all payments are equal — research and consulting reflect different relationships than speaking programs or meals.
Speaking / Promotional
Speaker programs, honoraria, and industry-sponsored educational events
$166,931 (78.5%)
Consulting
Expert advisory fees, typically reflecting recognized clinical expertise
$28,480 (13.4%)
Meals & Travel
Food, beverages, travel, and lodging — typically low-value
$17,283 (8.1%)
Payment trend by year
Annual totals from pharmaceutical and medical device companies.
2024
$18,774
2023
$13,004
2022
$11,762
2021
$8,670
2020
$13,780
2019
$54,323
2018
$92,381
Payments by company (2024)
Consulting
Speaking
Meals & Travel
Research
Takeda Pharmaceuticals U.S.A., Inc.
$69,745
Celgene Corporation
$28,941
Karyopharm Therapeutics Inc.
$26,859
Janssen Biotech, Inc.
$22,460
Janssen Scientific Affairs, LLC
$18,301
Seattle Genetics, Inc.
$13,542
GlaxoSmithKline, LLC.
$6,063
Verastem, Inc.
$3,750
AbbVie, Inc.
$3,221
PFIZER INC.
$1,421
Bayer HealthCare Pharmaceuticals Inc.
$1,388
Novartis Pharmaceuticals Corporation
$1,254
Epizyme, Inc.,
$1,250
AstraZeneca Pharmaceuticals LP
$1,075
Adaptive Biotechnologies Corporation
$986
E.R. Squibb & Sons, L.L.C.
$841
GENZYME CORPORATION
$780
Amgen Inc.
$736
Merck Sharp & Dohme LLC
$713
Incyte Corporation
$712
Genentech USA, Inc.
$542
Seagen Inc.
$530
Daiichi Sankyo Inc.
$521
BeiGene USA, Inc.
$455
Merck Sharp & Dohme Corporation
$454
Boehringer Ingelheim Pharmaceuticals, Inc.
$336
Astellas Pharma US Inc
$322
Lilly USA, LLC
$312
Blueprint Medicines Corporation
$312
Alexion Pharmaceuticals, Inc.
$294
ABBVIE INC.
$289
Eisai Inc.
$279
Ipsen Biopharmaceuticals, Inc
$218
Pharmacyclics LLC, An AbbVie Company
$212
PUMA BIOTECHNOLOGY, INC.
$199
EMD Serono, Inc.
$190
ARRAY BIOPHARMA INC
$187
Dendreon Pharmaceuticals LLC
$161
Regeneron Healthcare Solutions, Inc.
$159
Deciphera Pharmaceuticals Inc.
$149
TerSera Therapeutics LLC
$124
Puma Biotechnology, Inc.
$122
Bayer Healthcare Pharmaceuticals Inc.
$115
AVEO Pharmaceuticals, Inc.
$104
Spectrum Pharmaceuticals Inc.
$104
Janssen Products, LP
$100
Kite Pharma, Inc.
$89
Mirati Therapeutics, Inc.
$81
Taiho Oncology, Inc.
$73
Dova Pharmaceuticals
$72
AbbVie Inc.
$67
Sirtex Medical Inc
$65
Rigel Pharmaceuticals, Inc.
$64
Heron Therapeutics, Inc.
$63
Shire North American Group Inc
$60
Pharmacyclics LLC, an AbbVie Company
$59
TESARO, Inc.
$58
Gilead Sciences, Inc.
$57
Agios Pharmaceuticals, Inc.
$56
Exelixis Inc.
$52
Kyowa Kirin, Inc.
$51
ADC Therapeutics America, Inc.
$46
Lexicon Pharmaceuticals, Inc.
$45
Legend Biotech USA Inc.
$45
Clovis Oncology, Inc.
$44
MEDIVATION FIELD SOLUTIONS LLC
$43
TG THERAPEUTICS, INC.
$42
Aurobindo Pharma USA, Inc.
$40
Aveo Pharmaceuticals, Inc.
$40
JAZZ PHARMACEUTICALS INC.
$40
Emmaus Medical, Inc.
$38
Alnylam Pharmaceuticals Inc.
$38
G1 Therapeutics, Inc.
$35
MorphoSys, US Inc.
$29
Pharmacosmos Therapeutics Inc.
$29
Blue Earth Diagnostics Limited
$28
EISAI INC.
$27
SERVIER PHARMACEUTICALS LLC
$25
Myriad Genetic Laboratories, Inc.
$22
RECORDATI_RARE_DISEASES_INC.
$20
ImmunoGen, Inc.
$19
Coherus Biosciences Inc.
$19
SANOFI-AVENTIS U.S. LLC
$18
Stemline Therapeutics Inc.
$17
Partner Therapeutics, Inc.
$17
Advanced Accelerator Applications
$17
Sobi, Inc
$16
TAIHO ONCOLOGY, INC.
$15
SOBI, INC
$14
Acrotech Biopharma LLC
$13
Teva Pharmaceuticals USA, Inc.
$12
Helsinn Therapeutics (U.S.), Inc.
$12
Foundation Medicine, Inc.
$12
Iovance Biotherapeutics, Inc.
$11
Janssen Pharmaceuticals, Inc
$7
Top 3 companies account for 59.0% of total payments
Associated products mentioned in payments ›
ADAKVEO · ADCETRIS · AFINITOR · AKYNZEO · ALIMTA · ALUNBRIG · AUGTYRO · AYVAKIT · Abraxane · Alecensa · Aliqopa · Amtagvi · Avastin · Axumin · BAVENCIO · BELEODAQ · BENDEKA · BLENREP · BOSULIF · BRAFTOVI · BRUKINSA · Blincyto · CABLIVI · CABOMETYX · CALQUENCE · CARVYKTI · CERDELGA · CINVANTI · COSELA · CYRAMZA · Cabometyx · Cinvanti · Copiktra · DARZALEX · DOPTELET · Doptelet · ELIQUIS · ELITEK · ELREXFIO · EMPLICITI · ENHERTU · EPKINLY · ERLEADA · EVENITY · Elahere · Endari · Enhertu · FOTIVDA · FOUNDATIONONE · Folotyn · GATTEX · GAVRETO · GAZYVA · GILOTRIF · GIVLAARI · HYQVIA · IBRANCE · ICLUSIG · IDHIFA · IMBRUVICA · IMFINZI · IMLYGIC · INJECTAFER · INLYTA · INQOVI · Imbruvica · JADENU · JAKAFI · JEMPERLI · JEVTANA · KANJINTI · KEYTRUDA · KISQALI · KRAZATI · Kyprolis · LIBTAYO · LIBTAYO CEMIPLIMAB-RWLC INJECTION · LONSURF · LORBRENA · LUMAKRAS · LUPRON DEPOT · LUTATHERA · LYNPARZA · Lenvima · Leukine · Lonsurf · Lunsumio · Lutathera · MEKINIST · MONJUVI · MONOFERRIC · MVASI · MYLOTARG · MYRISK · NERLYNX · NINLARO · Nerlynx · Neulasta · Nexavar · Nplate · Nubeqa · OJJAARA · ONPATTRO · ONUREG · OPDIVO · OPDUALAG · OXBRYTA · Onivyde · Orserdu · PADCEV · PEMAZYRE · PIQRAY · PLUVICTO · POTELIGEO · PROMACTA · PROVENGE · PYRUKYND · Perjeta · Phesgo · Pomalyst · Poteligeo · QINLOCK · REBLOZYL · RETEVMO · RYBREVANT · Revlimid · Rezlidhia · Rubraca · SANDOSTATIN · SANDOSTATIN LAR · SARCLISA · SCEMBLIX · SHINGRIX · SIR-Spheres Microspheres · SOLIRIS · SOMATULINE DEPOT · SPRYCEL · SUTENT · SYLVANT · Somatuline Depot · Stivarga · TABRECTA · TAGRISSO · TASIGNA · TAZVERIK · TECENTRIQ · TECVAYLI · TEPMETKO · TIBSOVO · TIVDAK · TUKYSA · TUMOR LYSIS SYNDROME - DISEASE · Tazverik · Tecentriq · UKONIQ · ULTOMIRIS · Udenyca · Ultomiris · VELCADE · VENCLEXTA · VERZENIO · VOTRIENT · VPRIV · Vectibix · Venclexta · Vitrakvi · XALKORI · XARELTO · XGEVA · XOSPATA · XPOVIO · XTANDI · Xermelo · Xofigo · Xospata · Xtandi · Yescarta · ZEJULA · ZEPZELCA · ZYTIGA · Zevalin · Zoladex · clonoSEQ
Should you be concerned? Payments from pharmaceutical and device companies are legal and common — 57% of U.S. physicians receive at least one. They often reflect legitimate consulting, research, or education. What matters is whether a recommended drug or device appears in your doctor's payment records. If so, consider asking your doctor about it. How to interpret this data →
The majority of payments (78%) are for speaking programs and promotional activities, which reflect participation in industry-sponsored educational or marketing events. This is common in hematology and does not inherently indicate bias, but patients may wish to be aware. Total industry engagement is in the top 1% for hematology in FL.
Equivalent to $121 per 100 Medicare services performed
Geographic Context
Hematologists within 10 mi
11
Per 100K population
0.7
County median income
$81,115
Nearest hospital
HCA FLORIDA JFK HOSPITAL
3.2 mi
3.2 mi
Data Sources
| Provider Registry | ✓ NPPES | Weekly updates |
| Medicare Enrollment | ✓ PECOS | Monthly updates |
| Practice Data | ✓ Medicare Util. | Annual (CY lag) |
| Industry Payments | ✓ Open Payments | CY 2024 |
| Disciplinary History | — Not public | N/A |
This provider has data in 4 of 4 available federal datasets, with a Data Coverage level of Very High. This measures how much public data is available about a provider — not how good they are. How we calculate this →
Summary
Dr. Peles is a mixed practice specialist, with above-average Medicare volume (top 28% in FL), with speaking/promotional industry engagement in the top 1% of FL peers, with 19 years of NPI registration.
This summary is auto-generated from federal data. It describes data availability and patterns — not clinical quality. Read our methodology →
Frequently Asked Questions
Is Dr. Peles experienced with daratumumab injection (darzalex)?
Based on Medicare claims data, Dr. Peles performed 27,360 daratumumab injection (darzalex) services. Research suggests that higher procedure volume is often associated with better outcomes, particularly for complex procedures. Note that Medicare data only captures patients aged 65 and older, so the total practice volume across all patients is likely higher.
Does Dr. Peles receive payments from pharmaceutical companies?
Yes. Dr. Peles received a total of $212,694 from 95 companies across 1,234 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common among physicians — 57% of all U.S. physicians receive at least one industry payment. Patients may wish to ask their doctor about these relationships, especially if a recommended drug or device appears in the payment records.
How do Dr. Peles's costs compare to other hematologists in Palm Springs?
Dr. Peles's average Medicare payment per service is $17. Note that these figures represent what Medicare pays, not your out-of-pocket cost, which depends on your specific insurance plan and deductible. Procedure-level data above shows both what was submitted and what Medicare paid for each service type.
What does Data Coverage mean?
Data Coverage (currently Very High for Dr. Peles) measures how much public federal data is available about a provider. It is not a quality rating. A "Very High" or "High" level means the provider has data across multiple federal sources (NPPES, PECOS, Medicare Utilization, Open Payments), indicating a long track record of practice, Medicare participation, and industry disclosure. A "Low" or "Moderate" level may simply mean the provider is newer, does not see Medicare patients, or has not received any industry payments — none of which are inherently negative. Read our full methodology →
Is this data up to date?
Each data source has its own update cycle. Provider registry data (NPPES) is updated weekly. Medicare enrollment (PECOS) is updated monthly. Medicare practice data has a ~2 year lag — the most recent available is typically 2 years prior. Industry payment data (Open Payments) is published annually, usually in June, covering the prior calendar year. We display the data date prominently on each section so you always know how current it is. See our data freshness policy →
Explore related providers
Same specialty & city
Hematologists in Palm Springs
Browse hematologists in Palm Springs ranked by procedure volume and transparency data.
Highest volume
Top Hematologists in FL
Hematologists ranked by total Medicare services performed statewide.
Industry payments
Pharma Payments to Hematologists in FL
Which FL hematologists receive the most from drug and device companies.
By company
Takeda Pharmaceuticals U.S.A., Inc. Payments to Doctors
See all physicians who received payments from Takeda Pharmaceuticals U.S.A., Inc.
By company
Celgene Corporation Payments to Doctors
See all physicians who received payments from Celgene Corporation.
By company
Karyopharm Therapeutics Inc. Payments to Doctors
See all physicians who received payments from Karyopharm Therapeutics Inc.
About this page
All data on this page is sourced verbatim from public federal records published by the U.S. Centers for Medicare & Medicaid Services (CMS): NPPES ↗, Open Payments ↗, Medicare Provider Utilization ↗, and PECOS. Publication is mandated by the Physician Payments Sunshine Act (§6002 ACA, 42 U.S.C. §1320a-7h) and the Freedom of Information Act.
This page is not medical advice, an endorsement, a recommendation, or a quality rating. The Transparency Score measures data completeness — how much federal information exists for this provider — not clinical performance, patient outcomes, or quality of care. Always verify information directly with the provider and consult a licensed clinician before making medical decisions.
Provider corrections: Provider portal · Privacy questions: Privacy Policy · Terms: Terms of Use · Methodology: Methodology